Genomic Translation for Amyotrophic Lateral Sclerosis Care

NCT02795897 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 254

Last updated 2022-08-19

No results posted yet for this study

Summary

The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Matthew Harms, MD · Columbia University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2021-07-27
Completion
2022-06-29

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02795897 on ClinicalTrials.gov